Mylan launches 2 new generics

PITTSBURGH — Mylan on Monday announced the launch of two drugs following their approval by the Food and Drug Administration. The company will be rolling out its generic Glucotrol XL (glipizide) extended-release tablets and its generic Viramune XR (nevirapine) extended-release tablets. 

 

The glipizide, which will be available in 5- and 10-mg tablets, is indicated to assist adults with type 2 diabetes manage their glycemic control. The nevirapine, which will be available in 100-mg tablets, is an antiretroviral agent meant to be used alongside others to treat HIV-1 in adults and children over 6 years of age. 

 

The U.S. sales for nevirapine were $67,000 for the 12 months ended Sept. 30 and $70.7 million for the glipizide in the same period.